Blockchain Registration Transaction Record

GeoVax Raises $3M to Advance Mpox, COVID-19 Vaccines and Cancer Therapy

GeoVax Labs raises $3 million in private placement to fund development of mpox, smallpox, COVID-19 vaccines and cancer immunotherapy. Key programs include GEO-MVA and Gedeptin.

This financing enables GeoVax to advance critical vaccine and immunotherapy programs, including a pivotal Phase 3 trial for its mpox/smallpox vaccine (GEO-MVA) and next-gen COVID-19 vaccine (GEO-CM04S1), as well as its cancer therapy Gedeptin. For investors, it signals continued development of high-demand vaccines amid global health preparedness needs, potentially addressing unmet medical needs in biodefense and oncology.